{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T02:25:28Z","timestamp":1762050328661,"version":"3.40.5"},"reference-count":36,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.clml.2022.01.015","type":"journal-article","created":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T17:39:37Z","timestamp":1643909977000},"page":"e521-e525","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Comparison of Different Treatment Strategies for Blast-Phase Myeloproliferative Neoplasms"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2245-4068","authenticated-orcid":false,"given":"Franco","family":"Castillo Tokumori","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Najla","family":"Al Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Onyee","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Sallman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seongseok","family":"Yun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kendra","family":"Sweet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Padron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Lancet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rami","family":"Komrokji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew T.","family":"Kuykendall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2022.01.015_bib0001","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1080\/17474086.2016.1210004","article-title":"Blast-phase myeloproliferative neoplasms: risk factors and treatment approaches","volume":"9","author":"Pettit","year":"2016","journal-title":"Expert Rev Hemat"},{"key":"10.1016\/j.clml.2022.01.015_bib0002","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clml.2022.01.015_bib0003","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.leukres.2006.12.002","volume":"31","author":"Mesa","year":"2007","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2022.01.015_bib0004","series-title":"Leukemic Transformation in Myeloproliferative Neoplasms: A Literature Review on Risk, Characteristics, and Outcome","first-page":"1118","author":"Yogarajah","year":"2017"},{"key":"10.1016\/j.clml.2022.01.015_bib0005","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1182\/blood-2004-07-2864","article-title":"Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases","volume":"105","author":"Mesa","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.01.015_bib0006","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1182\/blood-2008-02-138230","article-title":"The natural history and treatment outcome of blast phase BCR-ABL\u2212 myeloproliferative neoplasms","volume":"112","author":"Tam","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.01.015_bib0007","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/hon.2737","article-title":"Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: real-world data","volume":"38","author":"Palandri","year":"2020","journal-title":"Hematol Oncol"},{"issue":"5","key":"10.1016\/j.clml.2022.01.015_bib0008","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1159\/000512929","article-title":"Accelerated phase of myeloproliferative neoplasms","volume":"144","author":"Shahin","year":"2021","journal-title":"Acta Haematol"},{"key":"10.1016\/j.clml.2022.01.015_bib0009","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.leukres.2018.05.004","article-title":"Outcomes and predictors of survival in blast phase myeloproliferative neoplasms","volume":"70","author":"Lancman","year":"2018","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2022.01.015_bib0010","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1016\/j.bbmt.2016.09.017","volume":"22","author":"Takagi","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"10.1016\/j.clml.2022.01.015_bib0011","first-page":"405","article-title":"Management of advanced phase myeloproliferative neoplasms","volume":"17","author":"Marcellino","year":"2019","journal-title":"Management"},{"key":"10.1016\/j.clml.2022.01.015_bib0012","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1182\/bloodadvances.2019001084","article-title":"Survival following allogeneic transplant in patients with myelofibrosis","volume":"4","author":"Gowin","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2022.01.015_bib0013","doi-asserted-by":"crossref","first-page":"E5401","DOI":"10.1073\/pnas.1407792111","article-title":"Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms","volume":"111","author":"Rampal","year":"2014","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.clml.2022.01.015_bib0014","doi-asserted-by":"crossref","first-page":"79126","DOI":"10.18632\/oncotarget.15988","article-title":"Azacitidine or intensive chemotherapy for older patients with secondary or therapy-related acute myeloid leukemia","volume":"8","author":"Dumas","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.clml.2022.01.015_bib0015","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.01.015_bib0016","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1159\/000506146","article-title":"Clinical benefit derived from decitabine therapy for advanced phases of myeloproliferative neoplasms","volume":"144","author":"Zhou","year":"2021","journal-title":"Acta Haematol"},{"key":"10.1016\/j.clml.2022.01.015_bib0017","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1182\/blood.2019000943","article-title":"Leukemia secondary to myeloproliferative neoplasms","volume":"136","author":"Dunbar","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.01.015_bib0018","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/sj.leu.2404914","article-title":"Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment","volume":"22","author":"Barosi","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.01.015_bib0019","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.01.015_bib0020","unstructured":"NCCN. Myeloproliferative neoplasms (Version 1.2020). Accessed: June 11 2021. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/mpn.pdf."},{"key":"10.1016\/j.clml.2022.01.015_bib0021","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2013-03-488098","article-title":"Revised response criteria for myelofibrosis: international Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report","volume":"122","author":"Tefferi","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.01.015_bib0022","doi-asserted-by":"crossref","first-page":"436","DOI":"10.3390\/jcm10030436","article-title":"Acute myeloid leukemia evolving from myeloproliferative neoplasms: many sides of a challenging disease","volume":"10","author":"Mannelli","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.clml.2022.01.015_bib0023","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1038\/s41375-020-0778-0","article-title":"A phase 1\/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia","volume":"34","author":"Bose","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.01.015_bib0024","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1182\/blood-2018-03-785907","article-title":"How I treat the blast phase of Philadelphia chromosome\u2013negative myeloproliferative neoplasms","volume":"132","author":"Odenike","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.01.015_bib0025","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1182\/blood-2017-03-772368","article-title":"Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States","volume":"130","author":"Muffly","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.01.015_bib0026","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1016\/j.leukres.2012.08.013","article-title":"Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium","volume":"36","author":"Mascarenhas","year":"2012","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2022.01.015_bib0027","doi-asserted-by":"crossref","first-page":"3572","DOI":"10.1182\/bloodadvances.2018019661","article-title":"Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms","volume":"2","author":"Rampal","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2022.01.015_bib0028","doi-asserted-by":"crossref","first-page":"4262","DOI":"10.1182\/blood.V128.22.4262.4262","article-title":"Phase I\/II study of ruxolitinib (RUX) with decitabine (DAC) in patients with post-myeloproliferative neoplasm acute myeloid leukemia (post-MPN AML): phase I results","volume":"128","author":"Bose","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.01.015_bib0029","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1038\/s41591-018-0233-1","article-title":"Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia","volume":"24","author":"Pollyea","year":"2018","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.clml.2022.01.015_bib0030","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1002\/ajh.26186","article-title":"Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: a multicenter series of 32 consecutive cases","volume":"96","author":"Gangat","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2022.01.015_bib0031","doi-asserted-by":"crossref","first-page":"10978","DOI":"10.1111\/jcmm.15730","article-title":"Bcl-xL represents a therapeutic target in Philadelphia negative myeloproliferative neoplasms","volume":"24","author":"Petiti","year":"2020","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.clml.2022.01.015_bib0032","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2021-151352","article-title":"Efficacy of HMA+\/-Venetoclax or intensive chemotherapy in blast-phase myeloproliferative neoplasms","volume":"138","author":"Yoon","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.01.015_bib0033","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML","volume":"378","author":"DiNardo","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.01.015_bib0034","doi-asserted-by":"crossref","first-page":"5336","DOI":"10.1182\/bloodadvances.2020001528","article-title":"Outcome of patients with IDH1\/2-mutated post\u2013myeloproliferative neoplasm AML in the era of IDH inhibitors","volume":"4","author":"Chifotides","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2022.01.015_bib0035","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1182\/bloodadvances.2018015875","article-title":"Targeted next-generation sequencing in blast phase myeloproliferative neoplasms","volume":"2","author":"Lasho","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2022.01.015_bib0036","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/ajh.24973","article-title":"Impact of gene mutations on treatment response and prognosis of acute myeloid leukemia secondary to myeloproliferative neoplasms","volume":"93","author":"Venton","year":"2018","journal-title":"Am J Hematol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022000301?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022000301?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T13:59:37Z","timestamp":1682949577000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265022000301"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":36,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S2152265022000301"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2022.01.015","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of Different Treatment Strategies for Blast-Phase Myeloproliferative Neoplasms","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2022.01.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}